UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 22, 2006
BRUKER BIOSCIENCES CORPORATION
(Exact name of registrant as specified in its charter)
|
Delaware |
|
000-30833 |
|
04-3110160 |
|
(State or other jurisdiction |
|
(Commission |
|
(IRS Employer |
|
of incorporation) |
|
File Number) |
|
Identification No.) |
40 Manning Road
Billerica, MA 01821
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (978) 663-3660
Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the reporting obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act
o Soliciting material pursuant to Rule 14a-12 of the Exchange Act
o Pre-commencement communications pursuant to Rule 14d-2(b) Exchange Act
o Pre-commencement communications pursuant to Rule 13e-4(c) Exchange Act
Section 2 – Financial Information
The information in this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
On February 22, 2006, Bruker BioSciences Corporation issued a press release announcing financial results as of and for the fourth quarter and year ended December 31, 2005. A copy of the press release is attached hereto as Exhibit 99.1.
Section 9 – Financial Statements and Exhibits
|
(c) |
|
Exhibits |
||
|
|
|
|
||
|
|
|
Number |
|
|
|
|
|
|
|
|
|
|
|
99.1 |
|
Press release dated February 22, 2006. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
BRUKER BIOSCIENCES CORPORATION |
|
|
|
(Registrant) |
|
|
|
|
|
|
Date: February 22, 2006 |
By: |
/s/ Frank H. Laukien, Ph.D. |
|
|
|
Frank H. Laukien, Ph.D. |
|
|
|
Chief Executive Officer and President |
3
Exhibit Index
Exhibit |
|
Exhibit Name |
|
Location |
|
|
|
|
|
|
|
99.1 |
|
Press release dated February 22, 2006. |
|
Furnished herewith* |
* Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
4